Two Sigma Advisers’s Elevation Oncology ELEV Stock Holding History

Two Sigma Advisers’s Portfolio ELEV Stock Details ELEV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-107,400	Closed	-$39.4K	–	2422
2025 Q2	$39.4K	Sell	107,400 -85,700	-44%	-$28.6K	﹤0.01%	2268
2025 Q1	$50K	Buy	193,100 +108,700	+129%	+$62.1K	﹤0.01%	2322
2024 Q4	$47.5K	Buy	84,400 +27,300	+48%	+$16.1K	﹤0.01%	2285
2024 Q3	$34.3K	Buy	+57,100	New	+$84.7K	﹤0.01%	2235
2024 Q1	–	Sell	-102,700	Closed	-$55.1K	–	2501
2023 Q4	$55.1K	Buy	102,700 +25,900	+34%	+$13.7K	﹤0.01%	2393
2023 Q3	$50.9K	Buy	+76,800	New	+$77.7K	﹤0.01%	2274

Other funds holding ELEV

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Two Sigma Advisers's ELEV Position: Q3 2025 in Review

Two Sigma Advisers sold out of Elevation Oncology (ELEV) in Q3 2025, closing a stake of 107,400 shares — an estimated $39.4K sold.

Two Sigma Advisers first reported a position in ELEV in Q3 2023 and held it in 6 quarters. The position peaked at $55.1K in Q4 2023. 1 fund tracked by Wall St. Rank holds ELEV as of Q3 2025.

Two Sigma Advisers reported no remaining Elevation Oncology position as of Q3 2025 after selling out during the quarter.
Two Sigma Advisers sold 107,400 Elevation Oncology shares in Q3 2025, an estimated $39.4K.
Two Sigma Advisers first reported a position in Elevation Oncology in Q3 2023 and held it in 6 quarters.
Two Sigma Advisers's Elevation Oncology position peaked at $55.1K in Q4 2023.
1 fund tracked by Wall St. Rank held Elevation Oncology as of Q3 2025.

Based on Two Sigma Advisers's 13F filing for Q3 2025, filed 14 Nov 2025.